Kymera Therapeutics, Inc.

NASDAQ:KYMR

44.44 (USD) • At close July 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q3
Revenue 22.17.3943.74125.6510.28747.8854.72816.5139.46616.1399.55111.5149.62215.27520.33618.51918.70212.78514.5333.2883.4281.8330.95
Cost of Revenue 0000000.90.90.90.81843.8770.700000000000
Gross Profit 22.17.3943.74125.6510.28747.8853.82815.6138.56615.321-34.32610.8149.62215.27520.33618.51918.70212.78514.5333.2883.4281.8330.95
Gross Profit Ratio 1111110.810.9450.9050.949-3.5940.93911111111111
Reseach & Development Expenses 80.25571.81760.4159.20248.81952.9748.11745.76742.22743.13343.87741.29335.94437.5338.30635.2225.96220.39215.77813.81912.11611.08611.31
General & Administrative Expenses 16.27116.33215.45517.37314.37414.22714.1214.12912.56511.63710.55611.03110.61111.7410.6678.0295.9095.1756.8383.6612.5592.531.501
Selling & Marketing Expenses 00000000000000000000000
SG&A 16.27116.33215.45517.37314.37414.22714.1214.12912.56511.63710.55611.03110.61111.7410.6678.0295.9095.1756.8383.6612.5592.531.501
Other Expenses 00004.925000000000000000000
Operating Expenses 96.52688.14975.86576.57568.11867.19762.23759.89654.79254.7754.43352.32446.55549.2748.97343.24931.87125.56722.61617.4814.67513.61612.811
Operating Income -74.426-80.755-72.124-50.925-57.831-19.312-57.509-43.383-45.326-38.631-44.882-40.81-36.933-33.995-28.637-24.73-13.169-12.782-8.083-14.192-11.247-11.783-11.861
Operating Income Ratio -3.368-10.922-19.279-1.985-5.622-0.403-12.163-2.627-4.788-2.394-4.699-3.544-3.838-2.226-1.408-1.335-0.704-1-0.556-4.316-3.281-6.428-12.485
Total Other Income Expenses Net 8.84510.0039.6378.8639.2744.9444.6424.5844.3983.7661.880.5530.2490.0940.0550.070.0940.0970.0970.2030.3150.270.441
Income Before Tax -65.581-70.752-62.487-42.062-48.557-14.368-52.867-38.799-40.928-34.865-43.002-40.257-36.684-33.901-28.582-24.66-13.075-12.685-7.986-13.989-10.932-11.513-11.42
Income Before Tax Ratio -2.967-9.569-16.703-1.64-4.72-0.3-11.182-2.35-4.324-2.16-4.502-3.496-3.813-2.219-1.405-1.332-0.699-0.992-0.55-4.255-3.189-6.281-12.021
Income Tax Expense 000004.996-0.8954.632-4.343-0.8181.916-0.553-0.2490.0510.1250.0980.118-0.3730.1250.2280.3490.30.445
Net Income -65.581-70.752-62.487-42.062-48.557-14.368-52.867-38.799-36.585-34.047-43.002-39.704-36.435-33.901-28.582-24.66-13.075-12.685-7.986-13.989-10.932-11.513-11.42
Net Income Ratio -2.967-9.569-16.703-1.64-4.72-0.3-11.182-2.35-3.865-2.11-4.502-3.448-3.787-2.219-1.405-1.332-0.699-0.992-0.55-4.255-3.189-6.281-12.021
EPS -0.82-0.88-0.82-0.58-0.69-0.25-0.9-0.67-0.63-0.59-0.79-0.77-0.71-0.66-0.56-0.55-0.29-0.29-0.18-0.32-0.25-0.26-0.26
EPS Diluted -0.82-0.88-0.82-0.58-0.69-0.25-0.9-0.67-0.63-0.59-0.79-0.77-0.71-0.66-0.56-0.55-0.29-0.29-0.18-0.32-0.25-0.26-0.26
EBITDA -63.461-68.706-60.44-40.063-47.027-13.451-51.926-37.851-39.973-33.989-42.199-39.516-35.943-33.162-27.841-24.08-12.566-12.161-7.468-13.575-10.511-11.122-11.258
EBITDA Ratio -2.872-9.292-16.156-1.562-4.571-0.281-10.983-2.292-4.223-2.106-4.418-3.432-3.736-2.171-1.369-1.3-0.672-0.951-0.514-4.129-3.066-6.068-11.851